Shaojie Chen

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Jinmao Zou · 4 shared papers, 2020–2025 · strength 0.68
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
2. Kaihong Huang · 4 shared papers, 2020–2025 · strength 0.68
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
3. Yinting Chen · 3 shared papers, 2020–2025 · strength 0.48
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
   • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗
4. Guoda Lian · 3 shared papers, 2020–2025 · strength 0.48
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
   • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗
5. Shangxiang Chen · 3 shared papers, 2020–2025 · strength 0.48
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
   • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗
6. Yaqing Li · 2 shared papers, 2020–2025 · strength 0.35
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
   • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗
7. Linjuan Zeng · 1 shared paper, 2025 · strength 0.26
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
8. Jiajia Li · 1 shared paper, 2025 · strength 0.26
   • Paper Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancre… DOI 10.1039/d5nr90172c↗
9. Ying Tan · 2 shared papers, 2020–2021 · strength 0.23
   • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
   • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗
10. Hanming Yao · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
11. Shurui Zhou · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
12. Jiajia Li · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
13. Yuzhou Huang · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
14. Yue Zhao · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
15. Yunlong Li · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
16. Ziyi Zhong · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
17. Kege Yang · 1 shared paper, 2024 · strength 0.20
    • Paper Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progr… DOI 10.1016/j.canlet.2024.216784↗
18. Zhenfeng Tian · 1 shared paper, 2021 · strength 0.13
    • Paper TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. DOI 10.1016/j.bcp.2020.114085↗
19. Qiubo Zhang · 1 shared paper, 2020 · strength 0.09
    • Paper Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. DOI 10.1002/cam4.2930↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.